Presentation
7 March 2022 The use of bioconjugates of porphyrin to overcome ABC drug transporter-mediated drug resistance
Author Affiliations +
Abstract
Rationally designed bioconjugates of photosensitizers have been shown to enhance the photochemical effect of photodynamic therapy (PDT) via altering the sub-cellular localization of the photosensitizers or modulating the function of ATP-binding cassette (ABC) transporters. P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) are the two key members that contribute to chemoresistance and PDT resistance in cancer. Here, we introduce a porphyrin-based phospholipid conjugation strategy to circumvent and inhibit the efflux function of ABC drug transporters. Our results show the porphyrin-phospholipid conjugate enhances the photosensitizer accumulation and modulates the enzymatic activity and protein integrity of ABCB1 and ABCG2.
Conference Presentation
© (2022) COPYRIGHT Society of Photo-Optical Instrumentation Engineers (SPIE). Downloading of the abstract is permitted for personal use only.
Barry J. Liang, Suresh V. Ambudkar, and Huang-Chiao Huang "The use of bioconjugates of porphyrin to overcome ABC drug transporter-mediated drug resistance", Proc. SPIE PC11940, Optical Methods for Tumor Treatment and Detection: Mechanisms and Techniques in Photodynamic and Photobiomodulation Therapy XXX, (7 March 2022); https://doi.org/10.1117/12.2609732
Advertisement
Advertisement
KEYWORDS
Resistance

Cancer

Photodynamic therapy

Proteins

Breast cancer

Modulation

Molecules

RELATED CONTENT


Back to Top